Evidence map›Paper›PMID 34648870›Full record

ArticleToxicology2021

Lung metabolome of 1,3-butadiene exposed Collaborative Cross mice reflects metabolic phenotype of human lung cancer.

Mary Nellis, Caitlin O Caperton, Ken Liu, ViLinh Tran, Young-Mi Go, Lance M Hallberg, Bill T Ameredes, Dean P Jones, Gunnar Boysen

Open access · greenAbstract read
In one paragraph

Article in Toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Mary NellisClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, 30322, United States.
Caitlin O CapertonDepartment of Environment and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States; The Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States.
Ken LiuClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, 30322, United States.
ViLinh TranClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, 30322, United States.
Young-Mi GoClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, 30322, United States.
Lance M HallbergDepartment of Preventive Medicine and Community Health, University of Texas Medical Branch, United States; Sealy Center for Environmental Health and Medicine, University of Texas Medical Branch, Galveston, TX, 77555, United States; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Bill T AmeredesSealy Center for Environmental Health and Medicine, University of Texas Medical Branch, Galveston, TX, 77555, United States; Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, United States; Division of Pulmonary, Critical Care, and Sleep Medicine, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Dean P JonesClinical Biomarkers Laboratory, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, GA, 30322, United States.
Gunnar BoysenDepartment of Environment and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States; The Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States. Electronic address: gboysen@uams.edu.
Emory University · USCenter for Environmental Health · USThe University of Texas Medical Branch at Galveston · USUniversity of Arkansas for Medical Sciences · USWinthrop Rockefeller Foundation · US

Funding

Pilot Project ProgramP30ES019776 · NIEHS · EMORY UNIVERSITY · PI Lance A Waller · 2013 to 2026
$22.6M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
Molecular Mechanisms of Environmental InjuryT32ES007254 · NIEHS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI AMEREDES, BILL T · 1990 to 2022
$6.6M
Vanadium in lung mitochondria oxidative stressR21ES031824 · NIEHS · EMORY UNIVERSITY · PI GO KANG, YOUNG-MI, JONES, DEAN PAUL · 2020 to 2021
$429k
Effects of Genetic Diversity on Carcinogen MetabolismR21ES023046 · NIEHS · UNIV OF ARKANSAS FOR MED SCIS · PI BOYSEN, GUNNAR · 2014 to 2015
$425k
A novel approach for quantitation of N-terminal valine adductsR21ES019684 · NIEHS · UNIV OF ARKANSAS FOR MED SCIS · PI BOYSEN, GUNNAR · 2011 to 2012
$405k
The Role of N1-Inosine Adducts in Butadiene MutagenesisF32ES013107 · NIEHS · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI BOYSEN, GUNNAR · 2003 to 2005
$89k
NCATS NIH HHS UL1 TR000039NIEHS NIH HHS F32 ES013107NIEHS NIH HHS P30 ES019776NIEHS NIH HHS R21 ES019684NIEHS NIH HHS R21 ES023046NIEHS NIH HHS R21 ES031824NIEHS NIH HHS T32 ES007254
6 · The paper itself

Abstract

1,3-Butadiene (BD) exposure is known to cause numerous adverse health effects, including cancer, in animals and humans. BD is metabolized to reactive epoxide intermediates, which are genotoxic, but it is not well know what other effects BD has on cellular metabolism. We examined the effects of exposure to BD on the mouse lung metabolome in the genetically heterogeneous collaborative cross outbred mouse model. Mice were exposed to 3 concentra-tions of BD for 10 days (2, 20, and 200 ppm), and lung tissues were analyzed using high-resolution mass spectrometry-based metabolomics. As compared to controls (0 ppm BD), BD had extensive effects on lung metabolism at all concentrations of exposure, including the lowest concentration of 2 ppm, as reflected by reprogramming of multiple metabolic pathways. Metabolites participating in glycolysis and the tricarboxylic acid cycle were elevated, with 8 out of 10 metabolites demonstrating a 2 to 8-fold increase, including the oncometabolite fumarate. Fatty acid levels, sphingosine, and sphinganine were decreased (2 to 8-fold), and fatty acyl-CoAs were significantly increased (16 to 31-fold), suggesting adjustments in lipid metabolism. Furthermore, metabolites involved in basic amino acid metabolism, steroid hormone metabolism, and nucleic acid metabolism were significantly altered. Overall, these changes mirror the metabolic alterations found in lung cancer cells, suggesting that very low doses of BD induce metabolic adaptations that may prevent or promote adverse health effects such as tumor formation.

Indexed as

MetabolomicsAnimalsButadienesCarcinogensCollaborative Cross MiceDose-Response Relationship, DrugFemaleHumansLipid MetabolismLungLung NeoplasmsMass SpectrometryMetabolomeMicePhenotype1,3-butadieneButadienesCarcinogens1,3-ButadieneCollaborative CrossLung metabolomeMetabolomics

Identifiers

PMID34648870
PMCPMC9062885
OpenAlexW3206943870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.